Skip to content

Study · Case report or series · n = 1 · 2026

4 results

Differing Presentations of Excess Visceral Abdominal Fat in People Living With HIV: Two Clinical Cases Highlighting Distinct Therapeutic Pathways With Tesamorelin and Glucagon-Like Peptide-1 Receptor Agonists.

Beach R, Tims-Cook Z, McGary CS, Thote T

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America1 May 2026

PMID42139091 (opens in a new tab)DOI10.1093/cid/ciag121 (opens in a new tab)PepBankPUB-42139091
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In an adult with well-controlled HIV and nonobese visceral adiposity, tesamorelin led to marked reductions in waist circumference.

    In plain wordsIn one adult with HIV and extra belly fat, tesamorelin was followed by a clear drop in waist size.

    Peptide
    Tesamorelin
    Outcome
    DecreaseWaist circumference
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Treatment with tesamorelin led to marked reductions in WC
    2 context sentences
    Summary · context
    The first patient demonstrated a nonobese visceral adiposity phenotype characterized by increased waist circumference (WC) and a BMI of 27 kg/m².
    Summary · context
    Two adults with well-controlled HIV presented with central adiposity.
  2. 02HumanCase report or seriesEfficacy outcome

    In an adult with well-controlled HIV and nonobese visceral adiposity, tesamorelin treatment was followed by improved lipid levels.

    In plain wordsIn one adult with HIV and extra belly fat, tesamorelin was followed by better blood fat levels.

    Peptide
    Tesamorelin
    Outcome
    Direction not reportedLipid levels
    Study

    n = 1

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Treatment with tesamorelin led to marked reductions in WC, improved lipid levels
    2 context sentences
    Summary · context
    The first patient demonstrated a nonobese visceral adiposity phenotype characterized by increased waist circumference (WC) and a BMI of 27 kg/m².
    Summary · context
    Two adults with well-controlled HIV presented with central adiposity.
  3. 03HumanCase report or seriesEfficacy outcome

    In an adult with well-controlled HIV and nonobese visceral adiposity, tesamorelin treatment was followed by enhanced functional well-being.

    In plain wordsIn one adult with HIV and extra belly fat, tesamorelin was followed by better day-to-day well-being.

    Peptide
    Tesamorelin
    Outcome
    IncreaseFunctional well-being
    Study

    n = 1

    Outcome group
    Exercise and physical function · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Treatment with tesamorelin led to marked reductions in WC, improved lipid levels, and enhanced functional well-being
    2 context sentences
    Summary · context
    The first patient demonstrated a nonobese visceral adiposity phenotype characterized by increased waist circumference (WC) and a BMI of 27 kg/m².
    Summary · context
    Two adults with well-controlled HIV presented with central adiposity.
  4. 04HumanCase report or seriesEfficacy outcome

    In a woman with obesity and persistent abdominal fat on an intermittently available GLP-1 receptor agonist, adding tesamorelin gave a more targeted approach to reduce visceral adiposity.

    In plain wordsIn one woman with obesity and HIV, adding tesamorelin to a GLP-1 drug was described as a more targeted way to reduce belly fat.

    Peptide
    Tesamorelin
    Outcome
    Direction not reportedVisceral adiposity after added tesamorelin
    Study

    n = 1

    Comparator
    GLP-1 receptor agonist alone
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Incorporation of tesamorelin provided a more targeted approach to reduce visceral adiposity in this context.
    2 context sentences
    Summary · context
    The second patient, a woman with higher BMI representative of obesity, received a GLP-1; however, her intermittent access to the medication resulted in fluctuating weight trends and persistent abdominal fat.
    Summary · context
    Two adults with well-controlled HIV presented with central adiposity.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.